A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...

The side effects that come with many cancer treatments can cause people to delay or avoid treatment.

Congruence secures a $5 million grant to advance innovative therapies for GBA1 Parkinson's disease, enhancing hope for ...

Gen Li, president and founder of Phesi, spoke with Pharmaceutical Executive about issues pharma companies are having during ...

The acquisition led by Advent International will see the two AI-powered companies combine forces to improve the healthcare ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis is accelerating investor interest, validating biomarker-driven ADCs, and shaping distinct strategic ...

Unlock the secrets of executive presence in pharma to inspire confidence, influence decisions, and elevate your leadership ...

Global leader in mother and childcare, Philips Avent, announced a partnership with March of Dimes to establish the modern-day ...

Planning and recruitment issues can compound during this critical phase of the drug development process. Gen Li, president ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.